Cattaneo, Dario
Pasina, Luca
Maggioni, Aldo Pietro
Giacomelli, Andrea
Oreni, Letizia
Covizzi, Alice
Bradanini, Lucia
Schiuma, Marco
Antinori, Spinello
Ridolfo, Annalisa
Gervasoni, Cristina http://orcid.org/0000-0002-4922-6495
Article History
Accepted: 21 October 2020
First Online: 5 November 2020
Declarations
:
: No sources of funding were used to conduct this study or prepare the manuscript.
: DC, LP, APM, AG, LO, AC, LB, MS, SA, AR, and CG have no conflicts of interest that are directly relevant to the content of this article. CG has received personal fees from MSD, ViiV, Gilead and Janssen Cilag unrelated to this study. DC has received personal fees from MSD, ViiV, and Janssen Cilag unrelated to this study. APM has received personal fees from Bayer, Fresenius, and Novartis for participating in study committees unrelated to this study.
: The study was approved by our hospital’s ethics committee (Comitato Etico Interaziendale Area 1).
: All of the patients included in the study signed an informed consent form for the administration of off-label treatments.
: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
: Research design and manuscript first draft: DC, CG. Provision of study materials or patients: AG, AC, LB, MS, SA, AR, CG. Data analysis: DC, LP, APM, and LO. Final manuscript approval: all authors.
Free to read: This content has been made available to all.